262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study
Kim, Y.H., Whittaker, S., Horwitz, S.M., Duvic, M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P., Wolter, P., Wang, Y., Palanca-Wessels, M., Zagadailov, E., Trepicchio, W.L., Lin, H., LittleVolume:
137
Language:
english
Journal:
Journal of Investigative Dermatology
DOI:
10.1016/j.jid.2017.02.278
Date:
May, 2017
File:
PDF, 240 KB
english, 2017